Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Biobanking Market Size Worth USD 2.69 billion by 2030: Exclusive Report by Growth Plus Reports

Published

on

Pune, July 05, 2022 (GLOBE NEWSWIRE) — The Global Biobanking Market is expected to clock USD ~2.69 billion by 2030 from valued at USD 1.85 billion in 2022, growing at a CAGR of 7.8% from 2022 to 2030 owing to increasing funding for research activities and growth in the number of biobanks in the past few years.

The global biobanking market is being driven by the development of regenerative medicine and its application in the treatment of cancer, Alzheimer’s disease, diabetes, and other genetic diseases. Biobanks store stem cells and umbilical cord tissue to aid in the development of regenerative medicines. Furthermore, with advancements in artificial intelligence, biobank has entered the big data era. This has resulted in higher-quality data and contributed to the shift toward data-driven science. Well-processed big data allows biobanks in different regions to collaborate and with advanced technology, these data can be easily handled. The cloud storage option also aids in resolving the issue of limited local storage.

Download Exclusive Sample of Report @ https://growthplusreports.com/inquiry/request-sample/biobanking-market/7617

The global biobanking market has been analyzed from five perspectives: Products & Services, Sample Type, Application, Storage Type and Region.

Market Driver

Significant growth in demand for cord blood banking is driving the growth of biobanks market on the global front. The increased awareness of numerous medicinal applications is blamed for the market expansion. Numerous NGOs, government agencies, business and public institutions, and other groups are raising awareness about the uses of cord banking. The ability to cure immunodeficiency illnesses is another benefit of cord blood banking technology, which profoundly alters the market. Blood and blood-forming organs are involved in hematological disorders, which include thalassemia, sickle cell anemia, leukemia, lymphoma, hemophilia, and other illnesses. These illnesses are becoming more and more common. The need for cord blood cells is expanding as a result of the exponentially increasing occurrence of leukemia cases around the world. Additionally, the development of the sector will be positively impacted by supportive government initiatives, quickly advancing healthcare infrastructure, and increased R&D for the treatment and diagnostics of various hematological illnesses.

Excerpts from ‘By Products & Services Segmentation’

Based on products & services, the biobanking market has been segmented into: –

  • Equipment
  • Consumables
  • software and services.

Equipment segment is further categorized into sample processing equipment, sample analysis equipment, storage equipment and sample transport equipment. Likewise, the services segment is also classified into sample collection services, sample processing services, sample analysis services, sample storage services and sample transport services. During the forecast period, the equipment segment is expected to dominate the global biobanking market. Because of the high capital investment required to acquire the equipment, so eventually generating more revenue. There is a broader range of equipment available for various processes such as sample collection, storage, processing and shipment. Equipment’s that are offered to provide different biobanking processes include: cell separators, freezers, thawing equipment, barcode readers, alarm and monitoring systems. Another prime factors such as the expansion in the number of biobanks globally, increasing technological advancements and new product release have played a key role in pushing the growth of this segment.

Request for Sample Pages of this Research Study: https://growthplusreports.com/inquiry/request-sample/biobanking-market/7617

Excerpts from ‘By Region Segmentation’

Based on the region, the global biobanking market has been segmented into:

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World (RoW).

Geographically, the biobanking market is dominated by North America, followed by Europe. The United States controlled majority of the market in North America. The increasing burden of chronic diseases and the increased emphasis on R&D activities are the major factors driving market growth in the United States.  According to the American Cancer Society, an estimated 1.9 million new cancer cases will be diagnosed in the United States in 2022, accounting for 609,360 cancer deaths. Because biobanks make it easier for researchers to obtain the volume, quality, and type of cancer tissue and data needed to accelerate their research, rising cancer incidences may increase R&D activities for cancer medications, contributing to market growth. Furthermore, strategic developments by key players may contribute to market growth. For example, in February 2021, Cincinnati Children’s Hospital Medical Center partnered with Down Syndrome Achieves (DSA) to establish a research biobank that will serve as a central repository for biospecimens donated by people with Down syndrome and their families.

Europe is the fastest growing, in terms of market size: factors such as expansion in research studies and growing funds for research activities are playing a crucial role in boosting the European biobanking market. The existence of well-recognized biobanks in the European countries such as Denmark, Norway, and Sweden have offered a considerable contribution towards the market growth. The European region is expected to grow at a significant rate during the forecast period owing to advancements in infrastructure for processing, storage, and retrieval of biospecimens. The BBMRI and EuroBioBank are two of the biggest biobanking networks presently operating in the region for bolstering research and medical activities.

Excerpts from ‘Competitive Landscape’

The renowned players operating in the global biobanking market are:

  • Thermo Fisher Scientific Inc
  • BD and Company
  • PHC Corporation
  • QIAGEN N.V
  • VWR International, LLC
  • Hamilton Company
  • Tecan Trading AG
  • Brooks Life Sciences
  • Greiner Bio-One International GmbH
  • Promega Corporation
  • Among others

VALUE PROPOSITIONS RELATED TO THE REPORT:

  • Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
  • Comprehensive quantitative and qualitative insights at segment and sub-segment level
  • Covid 19 impact trends and perspective
  • Granular insights at global/regional/country level
  • Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
  • Blanket coverage on competitive landscape
  • Winning imperatives
  • Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market

CUSTOMIZATION OPTIONS:

  • Distributor Landscape Assessment
  • Pricing Intelligence
  • Customer Base Assessment
  • Investment & Initiatives Analysis
  • ‘Business Profile’ of Key Players

Buy Full Report now at: https://growthplusreports.com/checkout?_token=zXYCaHsGNYTRd3aGVE12efEoEGuGtvqE1BwbYyfo&report_id=7617&license=Single&submit=

About Us:

Growth+Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth+ portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Tencent Announces Winners of Flagship CarbonX Program to Combat Climate Change

Published

on

tencent-announces-winners-of-flagship-carbonx-program-to-combat-climate-change

SHENZHEN, China, May 23, 2024 /PRNewswire/ — Tencent (00700.HK) is awarding 13 exceptional teams that won the first phase of its groundbreaking CarbonX Program, which is aimed at boosting promising new climate technologies. The winners, which emerged from a pool of 30 finalists and more than 300 initial applications, will receive a total of around RMB 100 million (US$14 million) in financial support from Tencent. It showcases the company’s commitment to driving sustainable social innovations in the fight against climate change.

CarbonX was launched in March 2023 to advance the next generation of low-carbon technologies. Tencent has committed RMB 200 million (US$28 million) in catalytic funding over the next three years to innovative ideas that might otherwise languish or fail to gain traction.
CarbonX’s first phase focused on carbon capture, utilization, and storage (CCUS), as well as technology-based carbon removal. These solutions were chosen for their unique ability to curb emissions from hard-to-abate industries such as steel and cement, mitigate the continued reliance on fossil fuels, and reduce legacy emissions created from decades of industrialization.
Backed by Tencent’s mission of Tech for Good and an alliance of like-minded industry partners, CarbonX aims to help these cutting-edge technologies make the leap from the research or early startup stage to commercial scale. The ultimate goal is supporting them in making a significant impact toward the targets outlined in the Paris Agreement, which includes a 45 percent reduction in emissions by 2030 and achieving net-zero emissions by 2050.
Dr. Hao Xu, Tencent’s Vice President of Sustainable Social Value and Head of Tencent’s Carbon Neutrality Lab, said: “Technology innovation serves as the driving force to accelerate our progress toward achieving carbon neutrality. CarbonX program is aimed at fostering the growth of these technologies, driving positive impact across society, and laying the groundwork for a more sustainable future.”
Professor Jerry Yan, Chair Professor of the Hong Kong Polytechnic University and Co-chairman of the CarbonX expert committee, said: “To pave the path for a greener economy, we must champion the development of cutting-edge low-carbon technologies. Just as solar and wind power were nurtured in their infancy, emerging solutions like CCUS and tech-based carbon removal demand our early support.”
The program assembled a panel of experts from academia, industries, and the investor community as the jury, and welcomed submissions from diverse participants across three distinct tracks:
CarbonX Lab: Designed to incubate research institutions, universities, or labs that bring in game-changing climate solutionsCarbonX Accelerator: Designed to accelerate the growth of climate-tech startups that exhibit commercialization potentialCarbonX Infrastructure: Designed to support capacity building to facilitate industry developmentThe finalists comprise four projects from the Lab track, six from the Accelerator track, and three from the Infrastructure track. These projects explore innovative solutions, such as using steel slag to capture and store carbon directly from furnace exhaust, converting CO2 into sustainable aviation fuel and valuable chemicals through electrochemical reactions or microorganisms, and employing new approaches to directly capture CO2 from the atmosphere with the hope of slashing the cost to less than US$150 per ton.
Meanwhile, Tencent is also collaborating with Tsinghua University to develop a comprehensive system of Measure, Reporting and Verification (MRV) tools to accurately gauge progress toward decarbonization.
Aside from receiving financial and advisory support, several projects will also have the opportunity to collaborate with industry partners and test their research beyond the laboratory setting.
Building upon the success of the first phase, Tencent is poised to launch the second iteration of CarbonX globally as early as later this year in pursuit of early-stage climate tech innovation.

View original content:https://www.prnewswire.co.uk/news-releases/tencent-announces-winners-of-flagship-carbonx-program-to-combat-climate-change-302153596.html

Continue Reading

Artificial Intelligence

NEXCOM Delivers Exceptional Performance in Edge AI Video Analytics

Published

on

nexcom-delivers-exceptional-performance-in-edge-ai-video-analytics

TAIPEI, May 23, 2024 /PRNewswire/ — NEXCOM, a leading supplier of network solutions, published AI and storage performance test results of its NSA 7160R: high-performance Edge server. NSA 7160R is powered by dual Intel® Xeon® Scalable processors for high computing, and enhanced with DDR5 memory, high-bandwidth PCIe Gen5 LAN modules, and high-capacity NVMe storage modules. The test results show the efficiency of the NSA 7160R in processing edge video server workloads and were explained in the accompanying paper. 

Edge AI Is the Future
With the rise of smart cities, processing data from cloud to the edge is becoming increasingly critical. Imagine the surge of visual data from ubiquitous security cameras – that information needs real-time analysis right where it’s collected. This is just the tip of the iceberg. As artificial intelligence permeates our lives, certain AI tasks will also need edge computing for efficient, lightning-fast performance. The key is to avoid bottlenecks in the data center by keeping things localized and streamlined.
Your Turnkey Solution Awaits
When it comes to Edge video servers, you need top-notch hardware and software that can handle all the “heavy lifting”. To speed up the total solution bringing up Intel comes in with their Intel® Edge Video Infrastructure (Intel® EVI) reference design. NEXCOM ran a bunch of tests using this design to evaluate its NSA 7160R for essential tasks including storage, image retrieval, and AI features such as inference and feature matching.
After conducting all tests, the results have shown that NSA 7160R meets all performance expectations with outstanding results. For a detailed breakdown of the solution description, test configuration, and results, please refer to the accompanying paper.
Intel, the Intel logo, and other Intel marks are trademarks of Intel Corporation or its subsidiaries.
About NEXCOM
Founded in 1992 and headquartered in Taipei, Taiwan, NEXCOM integrates its diverse capabilities and operates six global businesses, including the Network and Communication Solutions (NCS) unit. NCS focuses on the latest network technology and helps to build reliable network infrastructure, by delivering professional design and manufacturing services for customers all over the world. NCS’s network application platform is widely adopted in Cyber Security, Load Balancing, 5G uCPE, SD-WAN, SASE, Edge Computing, OT Security, Storage, NVR, and other network applications for businesses of all sizes.
Video – https://www.youtube.com/watch?v=4WlO8fyWnu4

View original content:https://www.prnewswire.co.uk/news-releases/nexcom-delivers-exceptional-performance-in-edge-ai-video-analytics-302153555.html

Continue Reading

Artificial Intelligence

Qiming Venture Partners Promotes Alex Zhou to Managing Partner

Published

on

qiming-venture-partners-promotes-alex-zhou-to-managing-partner

SHANGHAI, May 23, 2024 /PRNewswire/ — Qiming Venture Partners, a global-leading venture capital firm, is pleased to announce the promotion of Alex Zhou to Managing Partner.

As a Qiming home-grown Managing Partner, Alex first joined the firm in 2014 as a Vice President and has since emerged as one of the most active investors in frontier technologies, especially in the field of artificial intelligence. Alex will join fellow Managing Partners Duane Kuang, Nisa Leung and William Hu in managing Qiming’s operations.
In the past few years, Alex has actively participated in or led investments in many outstanding technology companies across the artificial intelligence, robotics, semiconductors, new energy vehicles, and software sectors. Notable among these include Roborock, UBTech, Unisound, Biren Technology, ROX Motor, VIEWTRIX Technology, Zhipu AI, Mech-Mind Robotics, Axera, HyperStrong, DeepWay, etc.
“I am deeply grateful for the guidance and trust I received from Qiming over the past 10 years.” Alex said. “We are at the forefront of a new wave of technological revolution. This era will undoubtedly bring about many bold innovators who will shape the future. Together with all the Managing Partners and colleagues at Qiming, I am excited and fully committed to seize the opportunities, embrace any potential challenges, explore new possibilities and build a better Qiming.”
Since its inception 18 years ago, Qiming has always committed to upgrading its institutional capabilities and team development in order to stay ahead in an ever-evolving technological and market landscape. The success achieved in the fields of healthcare, mobile internet and frontier technology is a testament to this strategic approach. Alex’s promotion to the most senior position in the firm demonstrates Qiming’s continued confidence in the future of technology innovation.
About Qiming Venture Partners
Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.
Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.
Many of our portfolio companies are today’s most influential firms in their respective sectors, including Xiaomi, Meituan, Bilibili, Zhihu, Roborock, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, Schrödinger, APT Medical, New Horizon Health, Sanyou Medical, AmoyDx, Berry Genomics, SinocellTech, UBTech, Yuanxin Technology, Caidya, Belief BioMed, WeRide, among many others.

View original content:https://www.prnewswire.co.uk/news-releases/qiming-venture-partners-promotes-alex-zhou-to-managing-partner-302153306.html

Continue Reading

Trending